Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biohaven Pharmaceuticals
Biotech
Ono pays $80M for local rights to trio of Biohaven IgG degraders
Japan’s Ono is paying $80 million upfront for regional rights to three of Biohaven’s IgG degraders, led by a phase 3-stage Grave’s disease prospect.
James Waldron
Oct 8, 2026 5:23am
Biohaven epilepsy drug suffers FDA hold days after $350M deal
Sep 10, 2026 10:03am
SK's $795M deal to usher Biohaven’s epilepsy therapy towards FDA
Aug 26, 2026 4:47am
Cue lines up new CMO and research head—Chutes & Ladders
Jul 17, 2026 8:30am
‘Bureaucratic idiocy’: GOP senator to investigate FDA rejections
Mar 10, 2026 11:10am
Biohaven reduces scope of R&D cuts as pipeline progresses
Mar 3, 2026 9:00am
